TriangleNCT00509041 · OUTCOME
24 Week Progression Free Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percentage of participants
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- 24 weeks
What was measured
Percentage of participants who were alive and progression free at 24 weeks. The 24 week progression free survival, with 95% confidence interval, was estimated using the Kaplan Meier method.
Groups in this outcome
Dasatinib
Use of dasatinib (50 mg orally twice a day) in treatment of pts with previously treated malignant mesothelioma
| Group | Source count |
|---|---|
| Dasatinib | 43 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Dasatinib | 23 | Not reported | 13.5 | 40 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 13.5
- upper Limit
- 40
- value
- 23
- denoms
- counts
- group Id
- OG000
- value
- 43
- units
- Participants
- description
- Percentage of participants who were alive and progression free at 24 weeks. The 24 week progression free survival, with 95% confidence interval, was estimated using the Kaplan Meier method.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Use of dasatinib (50 mg orally twice a day) in treatment of pts with previously treated malignant mesothelioma
- id
- OG000
- title
- Dasatinib
- param Type
- NUMBER
- reporting Status
- POSTED
- time Frame
- 24 weeks
- title
- 24 Week Progression Free Survival
- type
- PRIMARY
- unit Of Measure
- percentage of participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice